The Ohio Valley Node of the Clinical Trials Network

Information

  • Research Project
  • 10441828
  • ApplicationId
    10441828
  • Core Project Number
    UG1DA013732
  • Full Project Number
    3UG1DA013732-22S2
  • Serial Number
    013732
  • FOA Number
    PA-20-272
  • Sub Project Id
  • Project Start Date
    7/1/2021 - 4 years ago
  • Project End Date
    2/28/2022 - 3 years ago
  • Program Officer Name
    DOBBINS, RONALD
  • Budget Start Date
    7/1/2021 - 4 years ago
  • Budget End Date
    2/28/2022 - 3 years ago
  • Fiscal Year
    2021
  • Support Year
    22
  • Suffix
    S2
  • Award Notice Date
    8/26/2021 - 4 years ago

The Ohio Valley Node of the Clinical Trials Network

Using Integrative Data Analysis to Examine the Impact of Psychosocial Treatments for Black Cocaine Users Enrolled in the NIDA Drug Abuse Treatment Clinical Trials Network (CTN) Specific Aims Recent reports reveal that the acceleration of opioid-involved overdose deaths for Black people now outpaces that of White people.1 This increase is attributable to the presence of synthetic opioids (fentanyl) in the cocaine supply in approximately one third of opioid overdose deaths. The limited body of work available suggests that treatment effectiveness may vary across racial- ethnic groups. Yet, only a subset of these studies have specifically looked at cocaine use. The CTN provides a unique but underexplored collection of studies that can improve our knowledge on effective psychosocial treatments for Black people who use cocaine. The proposed study will combine data from 7 CTN treatment studies (total N = 1442 Black participants) that in combination present mixed findings. Using multiple emerging measurement/data analysis frameworks (integrative data analysis (IDA), meta-analysis of individual patient data (MIPD), causal moderation analysis), the goal of the proposed study is to evaluate the effectiveness of substance use disorder treatments for Black people who use cocaine. The project has three specific aims: Aim 1: Estimate scale scores of cocaine use severity while considering study-level measurement non-invariance. Aim 2: Compare the effectiveness of evidence-based treatment models for cocaine use severity. Aim 3: Explore individual- and study-level moderators, such as concomitant opioid use, age, sex, employment, pre-treatment psychiatric status, and retention to evaluate subgroup differences in treatment effectiveness.

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    UG1
  • Administering IC
    DA
  • Application Type
    3
  • Direct Cost Amount
    20521
  • Indirect Cost Amount
    12723
  • Total Cost
    33244
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    279
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NIDA:33244\
  • Funding Mechanism
    OTHER RESEARCH-RELATED
  • Study Section
  • Study Section Name
  • Organization Name
    UNIVERSITY OF CINCINNATI
  • Organization Department
    PSYCHIATRY
  • Organization DUNS
    041064767
  • Organization City
    CINCINNATI
  • Organization State
    OH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    452210001
  • Organization District
    UNITED STATES